Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2018

01-01-2018 | Images

Relapsed Myeloma with Hepatic Involvement and Tumour Lysis with Bortezomib

Authors: David Clark, Kyaw Dino Maw, Hesham Eldaly, Jason Smith, Joseph Padayatty

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2018

Login to get access

Excerpt

A 82 year old gentleman was diagnosed with IgG multiple myeloma and had treatment with attenuated cyclophosphamide, thalidomide and dexamethasone (CTDa) chemotherapy. Patient achieved a very good partial response. Fourteen months from the initial diagnosis, he presented with anaemia, renal impairment (creatinine 142 µmol/L) and hypercalcemia (2.65 mmol/L). The monoclonal M band and SFLC ratio rose from 2.0 to 22.0 g/L and 11 to 2016 respectively. Trephine biopsy confirmed 95% bone marrow infiltration by CD 138 positive cells (Fig. 1). β2microglobulin was 22 mg/L (range 1.2–2.4 mg/L). In addition, patient had deranged liver function tests; bilirubin 39 µmol/L, alkaline phosphatase 207 U/L and alanine transaminase 111 U/L. Clinical examination revealed non-tender hepatomegaly 5 cm below right sub-costal margin. A subsequent CT scan demonstrated hepatosplenomegaly (Fig. 2). The liver biopsy showed extensive infiltration by diffuse sheets of discohesive, highly atypical cells with plasmacytoid and blastic morphology (Fig. 3). Immunohistochemistry demonstrated strong reactivity for CD 138 (Fig. 4) and MUM1 with kappa light chain restriction.
Literature
1.
go back to reference Thomas FB, Clausen KP, Greenberger NJ (1973) Liver disease in multiple myeloma. Arch Intern Med 132(2):195–202CrossRefPubMed Thomas FB, Clausen KP, Greenberger NJ (1973) Liver disease in multiple myeloma. Arch Intern Med 132(2):195–202CrossRefPubMed
Metadata
Title
Relapsed Myeloma with Hepatic Involvement and Tumour Lysis with Bortezomib
Authors
David Clark
Kyaw Dino Maw
Hesham Eldaly
Jason Smith
Joseph Padayatty
Publication date
01-01-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0828-6

Other articles of this Issue 1/2018

Indian Journal of Hematology and Blood Transfusion 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine